Effective regimens for the treatment of Helicobacter pylori infection

Expert Opinion on Investigational Drugs

Volumn 15, Issue 9, 2006, Pages 995-1016

  Morgner, Andrea ^a   Labenz, Joachim ^b   Miehlke, Stephan ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Eradication therapy; Fluoroquinolones; Helicobacter pylori; Helicobacter pylori resistance; Rescue therapy; Rifabutin; Sequential therapy

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIOXIDANT; AZITHROMYCIN; BISMUTH CITRATE; BISMUTH DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; ESOMEPRAZOLE; FURAZOLIDONE; LACTOFERRIN; LANSOPRAZOLE; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; NITROIMIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLANT EXTRACT; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; RANITIDINE; RANITIDINE BISMUTH CITRATE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG HALF LIFE; DRUG MEGADOSE; ERADICATION THERAPY; GEOGRAPHIC DISTRIBUTION; HELICOBACTER INFECTION; HUMAN; LOW DRUG DOSE; MEDICAL PRACTICE; NONHUMAN; PHOTOTOXICITY; PRACTICE GUIDELINE; REVIEW; SINGLE DRUG DOSE; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; TREATMENT OUTCOME;

EID: 33748155310     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.9.995     Document Type: Review

References (189)

1. RAUWS EJ, TYTGAT GN: Helicobacter pylori in duodenal and gastric ulcer disease. Baillieres Clin. Gastroenterol. (1995) 9:529-547.
2. MALFERTHEINER P SIPPONEN P, NAUMANN M et al: Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am. J. Gastroenterol. (2005) 100:2100-2115.
3. ITO M, TANAKA S, KAMADA T, HARUMA K, CHAYAMA K: Causal role of Helicobacter pylori infection and eradication therapy in gastric carcinogenesis. World J Gastroenterol (2006) 12:10-16.
4. STOLTE M: Helicobacter pylori gastritis and gastric MALT lymphoma. Lancet (1992) 339:745-746.
5. WOTHERSPOON AC, DOGLIONI C, DISS TC et al: Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet (1993) 342:575-577.
6. ISAACSON PG, DU MQ: MALT lymphoma: from morphology to molecules. Nat. Rev. Cancer (2004) 4:644-653.
7. MORGNER A,THIEDE C, BAYERDORFFER E et al: Long-term follow-up of gastric MALT lymphoma after H. pylori eradication. Curr. Gastroenterol Rep. (2001) 3:516-522.
8. WUNDISCH T, THIEDE C, MORGNER A et al: Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin. Oncol (2005) 23:8018-8024.
9. McCOLL K, MURRAY L, EL-OMAR E et al.: Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N. Engl J Med. (1998) 339:1869-1874.
10. BLUM AL, TALLEY NJ, O'MORAIN C et al: Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus clarithromycin and amoxicillin. Effect One Year after Treatment (OCAY) Study Group. N. Engl. J Med (1998) 339:1875-1881.
11. MAZZOLENI LE, SANDER GB, OTT EA et al.: Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study. Dig. Dis. Sci. (2006) 51:89-98.
12. MOAYYEDI P, SOO S, DEEKS J et al: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst. Rev. (2006) 2:CD002096.
13. ABRAHAM NS, MOAYYEDI P, DANIELS B, VELDKUYZEN VAN ZANTEN SJ: Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Aliment. Pharmacol. Ther. (2004) 19:631-641.
14. DELANEY B, McCOLL K: Review article: Helicobacter pylori and gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. (2005) 22:32-40.
15. KUIPERS EJ, NELIS GF, KLINKENBERG-KNOL EC et al: Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut (2004) 53:12-20.
16. LANAS A: Prevention and treatment of NSAID-induced gastroduodenal injury. Curr. Treat. Options Gastroenterol. (2006) 9:147-156.
17. MADISCH A, MIEHLKE S, NEUBER F et al: Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy - a randomized, double-blind, placebo-concrolled multicentre trial. Aliment. Pharmacol. Ther. (2006) 23:473-479.
18. MORGNER A, RADKE J, RAPPEL S et al: Healing of active autoimmune gastritis by Helicobacter pylori eradication - a prospective, randomized, placebo-controlled, cross-over study. Gut (2002) 51:A31 (Abstract)
19. NILSSON HO, PIETROIUSTI A, GABRIELLI M, ZOCCO MA, GASBARRINI G, GASBARRINI A: Helicobacter pylori and extragastric diseases - other Helicobacters. Helicobacter (2005) 1:54-65.
20. FRANCHINI M: Thrombotic thrombocytopenic purpura: proposal of a new pathogenic mechanism involving Helicobacter pylori infection. Med. Hypotheses (2005) 65:1128-1131.
21. MALFERTHEINER P, MEGRAUD F, O'MORAIN C et al: European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2 - 2000 Consensus Report. Aliment. Pharmacol. Ther. (2002) 16:167-180.
22. HUNT R, FALLONE C, VELDHUYZEN VAN ZANTEN S et al: CHSG 2004 participants Canadian Helicobacter Study Group Consensus Conference: update on the management of Helicobacter pylori - an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection. Can. J. Gastroenterol. (2004) 18:547-554.
23. ASAKA M, SATOH K, SUGANO K et al: Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter (2001) 6:177-186.
24. GISBERT JP, GONZALEZ L, CALVET X et al: Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment. Pharmacol. Ther. (2000) 14:1319-1328.
25. GISBERT JP, PAJARES JM: Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment. Pharmacol. Ther. (2002) 16:1047-1057.
26. CHIBA N, LAHAIE R, FEDORAK RN, BAILEY R, VELDHUYZEN VAN ZANTEN SJ, BERNUCCI B: Helicobacter pylori and peptic ulcer disease. Current evidence for management strategies. Can. Fam. Physician (1998) 44:1481-1488.
27. MEGRAUD F, LAMOULIATTE H: Review article: the treatment of refractory Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2003) 17:1333-1343.
28. BROUTET N, TCHAMGOUE S, PEREIRA E, LAMOULIATTE H, SALOMON R, MEGRAUD F: Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Aliment. Pharmacol. Ther. (2003) 17:99-109.
29. BORODY TJ, CARRICK J, HAZELL SL: Symptoms improve after the eradication of gastric Campylobacter pyloridis. Med. J Aust. (1987) 146:450-451.
30. LAHEIJ RJ, ROSSUM LG, JANSEN JB, STRAATMAN H, VERBEEK AL: Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment. Pharmacol. Ther. (1999) 13:857-864.
31. LAMOULIATTE H, CAYLA R, MEGRAUD F et al: Amoxicillin-clarithromycin-omeprazole: the best therapy for Helicobacter pylori infection? Acta Gastroenterol, Belg. (1998) 56:140.
32. BAZZOLI F, ZAGARI M, POZZATO P et al: Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment. Pharmacol. Ther. (1998) 12:439-445.
33. CALVET X, GARCIA N, LOPEZ T, GISBERT JP, GENE E, ROQUE M: A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2000) 5:603-609.
34. LIND T, VELDHUYZEN VAN ZANTEN S, UNGE P et al: Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter (1996) 1:138-144.
35. LIND T, MEGRAUD F, UNGE P et al: The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology (1999) 116:248-253.
36. MALFERTHEINER P, BAYERDORFFER E, DIETE U et al.: The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment. Pharmacol, Ther. (1999) 13:703-712.
37. ZANTEN SJ, BRADETTE M, FARLEY A et al: The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment. Pharmacol. Ther. (1999) 13:289-295.
38. JANSSEN MJ, VAN OIJEN AH, VERBEEK AL, JANSEN JB, DE BOER WA: A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment. Pharmacol. Ther. (2001) 5:613-624.
39. PILOTTO A, FRANCHESCHI M, LEANDRO G et al.: Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. J. Gastroenterol. Hepatol (1999) 14:468-475.
40. HARRIS AW, MISIEWICS JJ, BARDHAN KD et al.: Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. Aliment. Pharmacol, Ther. (1998) 12:741-745.
41. LAMOULIATTE H, TALBI P, CAYLA R, ZERBIB F, MEGRAUD F: Randomised study comparing two seven days triple therapies with lansoprazole and two low-dose of clarithomycin plus amoxicillin or tinidazole for H. pylori eradication. Gut (1996) 39:A35 (Abstract).
42. 13C]urea breath rest is helpful to monitor H. pylori eradication after proton pump inhibitor-based triple therapy. Dig. Dis. Sci. (2000) 45:1330-1336.
43. MISIEWICS JJ, HARRIS AW, BARDHAN KD et al.: One week triple Therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut (1997) 41:735-739.
44. GISBERT JP, BOIXEDA D, ALLER R et al.: Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence. Med. Clin. Barc. (1999) 112:161-165.
45. HOUBEN MH, HENSEN EF, RAUWS EA et al.: Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or susceptible Helicobacter pylori strains. Aliment. Pharmacol. Ther. (1999) 13:883-889.
46. MIEHLKE S, SCHNEIDER-BRACHERT W, BÄSTLEIN E et al.: One-week triple therapy with esomeprazole, clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. Aliment. Pharmacol. Ther. (2003) 18:799-804.
47. VELDHUYZEN VAN ZANTEN S, LAURITSEN K, DELCHIER JC et al: One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment. Pharmacol. Ther. (2000) 14:1605-1611.
48. VELDHUYZEN VAN ZANTEN S, MACHADO S, LEE J: One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2003) 17:1381-1387.
49. BOCHENEK WJ, PETERS S, FRAGA PD et al: Helicobacter pylori Pantoprazole Eradication (HELPPE) Study Group. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter (2003) 8:626-642.
50. STABLES R, CAMPBELLI CJ, CLAYTON NM et al.: Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate. Aliment. Pharmacol. Ther. (1993) 7:237-246.
51. PETERSON WL, CIOCIOLA AA, SYKES DL, McSORLEY DJ, WEBB DD: Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. Aliment. Pharmacol. Ther. (1996) 10:251-261.
52. GISBERT JP, GONZALEZ L, CALVET X, ROQUE M, GABRIEL R, PAJARES JM: Helicobacter pylori eradication: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week - a meta analysis of efficacy Aliment, Pharmacol. Ther. (2000) 14:1141-1150.
53. GISBERT JP, GONZALEZ L, CALVET X: Systematic review and meta-analysis: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter (2005) 10:157-171.
54. MIDOLO PD, LAMBERT JR, KERR TG, TEE W: In vitro synergy between ranitidine bismuth citrate and tetracycline or clarithromycin against resistant strains of Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis, (1999) 18:832-834.
55. MEGRAUD F, ROBERTS P WILLIAMSON R: Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. Helicobacter (2000) 5:222-226.
56. CAMMAROTA G, CANNIZZARA O, TURSI A et al: One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. Aliment. Pharmacol. Ther. (1998) 12:539-543.
57. MIGNECO A, OJETTI V, SPECCHIA L et al.: Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension. Helicobacter (2003) 8:585-589.
58. POZZATO P, ZAGARI M, CARDELLI A et al: Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. Aliment. Pharmacol. Ther. (1998) 12:447-451.
59. CABOOTER M, DEKKERS CPM, THEODORS A, VANWEERTS S: Ranitidine bismuth citrate (RBC) or omeprazole (O) with clarithromycin (C) and amoxicillin (A) for 1 week in the eradication of H. pylori. Gastroenterology (1999) 116:A345 (Abstract).
60. BUJANDA L, SANCHEZ A, IRIONDO C, SANTOS A, COSME A, MUNO C: Comparative study of the eradication of Helicobacter pylori: ranitidine bismuth citrate versus omeprazole plus two antibiotics for seven days. Ann. Med. Intern. (2001) 18:361-363.
61. GEORGOPOULOS S, KARATAPANIS S, LADAS S et al: Lansoprazole versus ranitidine bismuth citrate based short-term triple therapies for Helicobacter pylori eradication: a randomized study with 6-months follow-up. Gut (1999) 45:A120 (Abstract).
62. GISBERT JP, CARPIO D, MARCOS S, GISBERT JL, GARCIA GRAVALOS R, PAJARES JM: One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. Eur. J. Gastroenterol. Hepatol. (2000) 12:489-495.
63. SUNG JJ, CHAN FK, WU JC et al: One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. Aliment. Pharmacol. Ther. (1999) 13:1079-1084.
64. SUNG JJ, LEUNG WK, LING TK et al: One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. Aliment. Pharmacol. Ther. (1998) 12:725-730.
65. TURSI A, BRANDIMARTE G, GIORGETTI G, MODEO ME, GIGLIOBLANCO A. Efficacy and tolerability of ranitidine bismuth citrate plus amoxycillin and clarithromycin as first- or second-line therapy to cure Helicobacter pylori infection. Hepatogastroenterology (2002) 49:1006-1009.
66. BUZAS GM, ILLYES G, SZEKELY E, SZELES I: Six regimens for the eradication of Helicobacter pylori (Hp) in duodenal ulcer patients: three consecutive trials (1995-1999). J Physiol. Paris. (2001) 95:437-441.
67. CESTARI R: Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. pylori Lombardy Group. Aliment. Pharmacol. Ther. (1998) 12:991-996.
68. FARUP PG, THOLFSEN J, WETTERNUS S, TORP R, HOIE O, LANGE OJ: Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. Scand J Gastroenterol. (2002) 37:1374-1379.
69. HETZEL DJ, DEKKERS C, COREMANS D, VANWEERTS S, DUGGAN AE: Ranitidine bismuth citrate (Pylorid) with low dose clarithromycin and metronidazole twice daily for one week gives high rates of H. pylori eradication. Gut (1997) 41:A206 (Abstract).
70. LANCASTER SMITH M, THATCHER P, MAISCHNER L, BEDWELL T, BEAZLEY S: Twice daily ranitidine bismuth citrate plus low dose clarithromycin and metronidazole for 7 days cures Helicobacter pylori infection. Gut (1998) 43:3155.
71. PYRE S, RIZZI R, BERTELLO PD: Two antisectretory drugs based one week regimens for eradication of Helicobacter pylori (Hp) in duodenal ulcer (DU) patients. Gut (1998) 43:3188 (Abstract).
72. GUDJONSSON H, BARDHAN KD, HOIE O et al: High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. Aliment. Pharmacol Ther. (1998) 12:1113-1119.
73. CAMMAROTA G, CANNIZZARO O, CIANCI R et al: Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection. Dig. Dis. Sci. (1999) 44:2386-2389.
74. BARDHAN KD, WURZER H, MARCELINO M, JAHNSEN J, LOTY N, ROBERTS PM: Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. Am. J. Gastroenterol. (1998) 93:380-385.
75. HOFFMAN JS, KATZ LM, CAVE DR: Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. (1999) 13:503-506.
76. PYRE S, RIZZI R, GELCI L: A randomized study comparing two ranitidine bismuth citrate (RBC) based regimens to cure Helicobacter pylori (Hp) infection in duodenal ulcer (DU) patients. Gut (2000) 47:A110 (Abstract).
77. VAN DER WOUDEN EJ, THIJS JC, VAN ZWET AA, KOOY A, KLEIBAUKER JH: One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. Am. J. Gastroenterol. (1998) 93:1228-1231.
78. GRAHAM DY, LEW GM, MALATY HM et al.: Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology (1992) 102:493-496.
79. PENSTON JG: Review article: Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment. Pharmacol. Ther. (1994) 8:369-389.
80. NAKAJIMA S, GRAHAM DY, HATTORI T, BAMBA T. Strategy for treatment of Helicobacter pylori infection in adults. II. Practical policy in 2000. Curr. Pharm. Des. (2000) 6:1515-1529.
81. KIRSCH C, MORGNER A, MIEHLKE S: Relevance of cytochrome P450 polymorphism in the treatment of Helicobacter pylori infection and gastroesophageal reflux disease. Curr. Pharmacogenomics (2006) 4:47-56.
82. MEGRAUD F, HAZELL S, GLUPCZYNSKI Y. Antibiotic susceptibility and resistance. In: Helicobacter pylori: physiology and genetics. Mobley HLT (Ed.), ASM Press, Washington DC, USA (2001):511-530.
83. DE BOER WA, BORODY TJ: Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy. Dig. Liver. Dis. (2000) 32:673-675.
84. MEGRAUD F: H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut (2004) 53:1374-1384.
85. GLUPCZYNSKI Y, MEGRAUD F, LOPEZ-BREA M, ANDERSEN LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. E. J. Clin. Microbiol. Infect. Dis. (2001) 20:820-823.
86. DUCK WM, SOBEL J, PRUCKLER JM et al: Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg. Infect. Dis. (2004) 10:1088-1094.
87. VAKIL N, HAHN B, McSORLEY D: Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am. J. Gastroenterol. (1998) 93:1432-1435.
88. PEREZ ALDANA L, KATO M, NAKAGAWA S et al: The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter (2002) 7:306-309.
89. HOUBEN MH, VAN DE BEEK D, HENSEN EF, CRAEN AJ, RAUWS EA, TYTGAT GNA: Systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment. Pharmacol. Ther. (1999) 13:1047-1055.
90. PILOTTO A, RASSU M, LEANDRO G, FRANCESCHI M, DI MARIO F: Interdisciplinary Group for the Study of Ulcer. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig. Liver Dis. (2000) 32:763-768.
91. KATO M, YAMAOKA Y, KIM JJ et al: Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob. Agents Chemother. (2000) 44:2214-2216.
92. TORRES J, CAMORLINGA-PONCE M, PEREZ-PEREZ G et al: Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin. Microbiol. (2001) 39:2677-2680.
93. LUI SY, YEOH KG, HO B: Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multi-ethnic Asian population. J Clin. Microbiol. (2003) 41:5011-5014.
94. DEBETS-OSSENKOOP YJ, HERSCHEID AJ, POT RG, KUIPERS EJ, KUSTERS JG, VANDENBROUKE-GRAULS CM: Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in the Netherlands. J. Antimicrob. Chemother. (1999) 43:511-515.
95. BOYANOVA L, MENTIS A, GUBINA M et al: The status of antimicrobial resistance of Helicobacter pylori in Eastern Europe. Clin. Microbiol. Infect. (2002) 8:388-396.
96. MOORE RA, BECKTHOLD B, WONG S, KUREISHI A, BRYAN LE: Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob. Agents Chemother. (1995) 39:107-111.
97. TANKOVICS J, LASCOLS C, SCULO Q, PETIT JC, SOUSSY CJ: Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob. Agents Chemother. (2003) 47:3942-3944.
98. CABRITA J, OLEASTRO M, MATOS R et at: Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J. Antimicrob. Chemother. (2000) 46:1029-1031.
99. AKADA JK, SHIRAI M, FUJII K, OKITA K, NAKAZAWA T: In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657. Antimicrob. Agents Chemother. (1999) 43:1072-1076.
100. HEEP M, BECK D, BAYERDORFFER E, LEHN N: Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob. Agents Chemothr. (1999) 43:1497-1499.
101. MIEHLKE S, HANSKY K, SCHNEIDER-BRACHERT et al: Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment. Pharmacol. Ther. (2006) 24:395-403.
102. GISBERT JP, GISBERT JL, MARCOS S, OLIVARES D, PAJARES JM: Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment. Pharmacol. Ther. (2005) 22:1041-1046.
103. TORACCHIO S, CAPODICASA S, SORAJA DB, CELLINI L, MARZIO L: Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig. Liver Dis. (2005) 37:33-38.
104. GISBERT JP, CALVET X, BUJANDA L, MARCOS S, GISBERT JL, PAJARES JM: 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter (2003) 8:90-94.
105. HEEP M, RIEGER U, BECK D, LEHN N: Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (2000) 44:1075-1077
106. TREIBER G, AMMON S, MALFERTHEINER P, KLOTZ U: Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter (2002) 7:225-231.
107. HAAS CE, NIX DE, SCHENTAG JJ: In vitro selection of resistant Helicobacter pylori. Antimicrob. Agents Chemother. (1990) 34:1637-1641.
108. QASIM A, SEBASTIAN S, THORNTON O et al: Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment. Pharmacol Ther. (2005) 21:91-96.
109. HOFMAN P, WAIDNER B, HOFMAN V, BERESWILL S, BREST P, KIST M: Pathogenesis of Helicobacter pylori infection, Helicobacter (2004) 9:15-22.
110. XIANG Z, CENSINI S, BAYELI PF et al: Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect. Immun. (1995) 63:94-98.
111. ATHERTON JC, CAO P, PEEK RM Jr, TUMMURU MK, BLASER MJ, COVER TL: Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J. Biol. Chem. (1995) 270:17771-17777.
112. VAN DOORN LJ, SCHNEEBERGER PM, NOUHAN N, PLAISIER AP, QUINT WG, DE BOER W: Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut (2000) 46:321-326.
113. RUDI J, REUTHER S, SIEG A, HOERNER M, STREMMEL W: Relevance of underlying disease and bacterial vacA and cagA status on the efficacy of Helicobacter pylori eradication. Digestion (2002) 65:11-15.
114. GISBERT JP, HERMIDA C, PAJARES JM: Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in non-ulcer dyspepsia? Hepatogastroenterology (2001) 48:1383-1388.
115. HUANG J, HUNT RH: The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment. Pharmacol. Ther. (1999) 13:719-729.
116. O'CONNOR HJ, LOANE J, BINDEL H, BHUTTA AS, CUNNANE K: One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit? Helicobacter (1997) 2:199-204.
117. GISBERT JP, DOMINGUEZ-MUNOZ A, DOMINGUEZ-MARTIN A, GISBERT JL, MARCOS S: Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? Am. J. Gastroenterol. (2005) 100:1935-1940.
118. GODDARD AF: Review article: factors influencing antibiotic transfer across the gastric mucosa. Aliment. Pharmacol. Ther. (1998) 12:1175-1184.
119. ERAH PO, GODDARD AF, BARRETT DA, SHAW PN, SPILLER RC: The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. (1997) 39:5-12.
120. VERGARA M, VALLVE M, GISBERT JP, CALVET X: Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol Ther. (2003) 18:647-654.
121. GISBERT JP, PAJARES JM: Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. Dig. Liver Dis. (2004) 36:253-259.
122. HSU PI, LAI KH, LIN CK et al.: A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am. J. Gastroenterol. (2005) 100:2387-2392.
123. ANAGNOSTOPOULOS GK, TSIAKOS S, MARGANTINIS G, KOSTOPOULOS P, ARVANITIDIS D: Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. J. Clin. Gastroenterol. (2004) 38:503-506.
124. SHEU BS, KAO AW, CHENG HC et al.: Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment. Pharmacol. Ther. (2005) 21:283-288.
125. VALLVE M, VERGARA M, GISBERT JP, CALVET X: Single versus double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment. Pharmacol. Ther. (2002) 16:1149-1156.
126. HUANG J, HUNT RH: The importance of clarithromycin dose in the management of Helicohacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment. Pharmacol. Ther. (1999) 13:719-729.
127. BEALES ILP: Efficacy of Helicobacter pylori eradication therapies: a single centre observational study. BMC Gastroenterol. (2001) 1:7-15.
128. DELLA MONICA P, LAVAGNA A, MASOERO G, LOMBARDO L, CROCELLA L, PERA A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment. Pharmacol. Ther. (2002) 16:1269-1275.
129. PENSTON JG, MISTRY KR: Eradication of Helicobacter pylori in general practice. Aliment. Pharmacol. Ther. (1996) 10:139-145.
130. O'MORAIN C, MONTAGUE S: Challenges to therapy in the future. Helicobacter (2000) 5:23-26.
131. LAMOULIATTE H, MEGRAUD F, DELCHIER JC et al.: Multicentre Study Group Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment. Pharmacol. Ther. (2003) 18:791-797.
132. HOJO M, MIWA H, NAGAHARA A, SATO N: Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand. J. Gastroenterol. (2001) 36:690-700.
133. PERRI F, FESTA V, MERLA A, BARBERANI F, PILOTTO A, ANDRIULLI A: Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy' Aliment. Pharmacol. Ther. (2003) 18:815-820.
134. GRAHAM DY, OSATO MS, HOFFMAN J et al.: Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment. Pharmacol, Ther. (2000) 14:745-750.
135. MIEHLKE S, KIRSCH C, SCHNEIDER-BRACHERT W et al.: A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter (2003) 8:310-319.
136. PERRI F, VILLANI MR, QUITADAMO M, ANNESE V, NIRO GA, ANDRIULLI A: Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? Aliment. Pharmacol. Ther. (2001) 15:1017-1022.
137. GISBERT JP, FUENTES J, CARPIO D et al.: 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. Aliment. Pharmacol. Ther. (2005) 21:1249-1253.
138. ROMANO M, MARMO R, CUOMO A et al: Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin. Gastroenterol. Hepatol. (2003) 1:273-278.
139. TORACCHIO S, CELLINI L, DI CAMPLI E et al.: Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment. Pharmacol. Ther. (2000) 14:1639-1643.
140. NERI M, MILANO A, LATERZA F et al.: Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment. Pharmacol. Ther. (2003) 18:821-827.
141. BREUER T, GRAHAM DY. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am. J. Gastroenterol. (1999) 94:725-729.
142. CAMMAROTA G, MARTINO A, PIROZZI G et al.: High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2004) 19:789-795.
143. BAYERDORFFER E, MIEHLKE S, LEHN N et al.: Double blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology (1995) 108:1412-1417.
144. BAYERDORFFER E, NEUBAUER A, RUDOLPH B et al.: Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet (1995) 345:1591-1594.
145. MIEHLKE S, MANNES GA, LEHN N, BAYERDORFFER E, HELE C, STOLTE M: An increasing dose of omeprazole combined with amoxicillin cures Helicobacter pylori infection more effectively. Aliment. Pharmacol. Ther. (1997) 11:323-329.
146. JAUP B: Dual 'rescue' therapy for eradication of H. pylori in previous triple therapy failure. Gut (1999) 45-A118 (Abstract).
147. PEITZ U, GLASBRENNER B, ELLENRIEDER V et al.: Re-treatment of H. pylori infection with high-dose omeprazole-amoxicillin after failure with metronidazole-clarithromycin combination. Gut (1999) 45:A111 (Abstract).
148. ELLENRIEDER V, BOECK W, RICHTER C, MARRE R, ADLER G, GLASBRENNER B: Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scand. J. Gastroenterol. (1999) 34:750-756.
149. GISBERT JP, PAJARES JM: Helicobacter pylori 'rescue' therapy after failure of two eradication treatments. Helicobacter (2005) 10:363-372.
150. MALATY H, EL-ZIMATY HM, GENTA RM, COLE RA, GRAHAM DY: High-dose proton
151. MIEHLKE S, SCHNEIDER-BRACHERT W, MORGNER A et al.: One-week once-daily triple therapy with esomeprazole, moxifloxacin and rifabutin is effective in the treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Gastroenterology (2006) 130-A93 (Abstract).
152. TORACCHIO S, CAPODICASA S, SORAJA DB, CELLINI L, MARZIO L: Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig. Liver Dis. (2005) 37:33-38.
153. CANDUCCI F, OJETTI V, POLA P, GASBARRINI G, GASBARRINI A: Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. Aliment. Pharmacol. Ther. (2001) 15:143.
154. WONG WM, GU Q, LAM SK et al.: Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy versus quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment. Pharmacol, Ther. (2003) 17:553-560.
155. PERRI F, FESTA V, CLEMENTE R, QUITADAMO M, ANDRIULLI A: Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment. Pharmacol, Ther. (2000) 14:311-316.
156. BOCK H, KOOP H, LEHN N, HEEP M: Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. J. Clin. Gastroenterol. (2000) 31:222-225.
157. BORODY TJ, PANG G, WETTSTEIN AR et al.: Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2006) 23:481-488.
158. PERRI F, FESTA V, CLEMENTE R et al.: Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am. J. Gastroenterol. (2001) 96:58-62.
159. LAMARQUE D, TANKOVIC J, BERRHOUMA A et al.: Triple therapy using ciprofloxacin for eradication of clarithromycin and metronidazole-resistant
160. GISBERT JP, MORENA F: Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment. Pharmacol. Ther. (2006) 23:35-44.
161. SAAD RJ, SCHOENFELD P, KIM HM, CHEY WD: Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am. J. Gastroenterol. (2006) 101:488-496.
162. GISBERT JP, CASTRO-FERNANDEZ M, BERMEJO F et al.: Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am. J. Gastroenterol. (2006) 101:243-247.
163. GISBERT JP: Rescue therapy with levofloxacin after multiple H. pylori treatment failures. Aliment. Pharmacol. Ther. (2005) 22:653-654.
164. DE SARRO A, DE SARRO G: Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr. Med Chem. (2001) 8:371-384.
165. DI CARO S, OJETTIi V, ZOCCO MA et al.: Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. (2002) 16:527-532.
166. NISTA EC, CANDELLI M, ZOCCO MA et al.: Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2005) 21:1241-1247.
167. COELHO LG, MORETZSOHN LD, VIEIRA WL et al.: New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment. Pharmacol. Ther. (2005) 21:783-787.
168. KAMIJI MM, DE OLIVEIRA RB: Non-antibiotic therapies for Helicobacter pylori infection. Eur. J. Gastroenterol, Hepatol. (2005) 17:973-981.
169. ZULLO A, VAIRA D, VAKIL N et al.: High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment. Pharmacol. Ther. (2003) 17:719-726.
170. HASSAN C, DE FRANCESCO V, ZULLO A et al.: Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment. Pharmacol. Ther. (2003) 18:641-646.
171. DE FRANCESCO V, ZULLO A, MARGIOTTA M et al.: Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment. Pharmacol. Ther. (2004) 19:407-414.
172. ZULLO A, GATTA L, DE FRANCESCO V et al.: High rate of Helirobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment. Pharmacol. Ther. (2005) 21:1419-1424.
173. FRANCAVILLA R, LIONETTI E, CASTELLANETA SP et al.: Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology (2005) 129:1414-1419.
174. SACCIONOCCE G, HASSAN C, PANARESE A, PIGLIONICA D, MORINI S, ZULLO A: Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. Can. J. Gastroenterol. (2006) 20:113-117.
175. DE FRANCESCO V, MARGIOTTA M, ZULLO A et al.: Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann. Intern. Med. (2006) 144:94-100.
176. DIAL EJ, ROMERO JJ, HEADON DR, LICHTENBERGER LM: Recombinant human lactoferrin is effective in the treatment of Helicobacter felis-infected mice. J. Pharm. Pharmacol. (2000) 52:1541-1546.
177. MIEHLKE S, REDDY R, OSATO MS, WARD PP, CONNEELY OM, GRAHAM DY: Direct activity of recombinant human lactoferrin against Helicobacter pylori. J. Clin. Microbiol. (1996) 34:2593-2594.
178. GUTTNER Y, WINDSOR HM, VIIALA CH, MARSHALL BJ: Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2003) 17:125-129.
179. DI MARIO F, ARAGONA G, DAL BO ND et al.: Use of lactoferrin for Helicobacter pylori eradication. Preliminary results. J. Clin. Gastroenterol. (2003) 36:396-398.
180. DI MARIO F, ARAGONA G, DAL BO N et al.: Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment. Pharmacol. Ther. (2006) 23:1235-1240.
181. ZULLO A, DE FRANCESCO V, SCACCIONOCE, G et al.: Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multicentre study. Dig. Liver Dis. (2005) 37:496-500.
182. BILARDI C, DULBECCO P, ZENTILIN P et al.: A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin. Gastroenterol. Hepatol, (2004) 2:997-1002.
183. GISBERT JP, GISBERT JL, MARCOS S, OLIVARES D, PAJARES JM: 7-day ranitidine bismuth citrate- versus levofloxacin-based triple therapy after H. pylori treatment failure. Helicobacter (2005) 10:533 (Abstract).
184. NISTA EC, CANDELLI M, CREMONINI F et al.: Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment. Pharmacol. Ther. (2003) 18:627-633.
185. NISTA EC, CANDELLI MMS: Levofloxacin-based triple therapy in second-line treatment for H. pylori eradication: update. Gastroenterology (2005) 128:427 (Abstract)
186. NISTA EC, CANDELLI M, FINI L et al.: 10 days levofloxacin-based triple therapy in second-line treatment for Helicobacter pylori eradication. Gastroenterology (2004) 126:576.
187. ORSI P, PINAZZI O, ARAGONA G, DI MARIO F: Rabeprazole/levofloxacin based triple therapy as a salvage treatment after failure of H. pylori eradication with standard regimens. Helicobacter (2003) 8:339-493.
188. PERRI F, FESTA V, MERLA A, BARBERANI F, PILOTTO A, ANDRIULLI A: Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy. Aliment. Pharmacol. Ther. (2003) 18:815-820.
189. WONG WM, GU Q, LAM SK et al.: Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2003) 17:553-560.